Mutación del gen BRAF en pacientes con cánceres de colon y recto con KRAS no mutado
Date
2014
Type:
Artículo
item.page.extent
6
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Sociedad Médica de Santiago
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Background: In colorectal cancer, BRAF and KRAS mutation are mutually
exclusive, but both are independent prognostic factors for the disease. Aim: To
determine the frequency of BRAF V600E mutation in colorectal cancer. Material
and Methods: A KRAS mutation study was carried out in 100 tissue samples
of primary and metastatic adenocarcinomas of colon and rectum from patients
aged 61.1 ± 62 years (56 women). Negative KRAS mutation cases underwent
study of BRAF V600E mutation by restriction fragment length polymorphism
(RFLP) and direct sequencing. Results: Primary tumors were located in the colon
and rectum in 88 and six cases respectively. Five were liver metastases and in
one case, the sample location was undetermined. Forty two samples were KRAS
positive (mutated). In 12 of the 58 KRAS negative (wild type) samples, the V600E
mutation in codon 15 of the BRAF gene was demonstrated. No differences in
the frequency and distribution of mutations, stratified by gender, age, primary
tumor versus metastasis, or tumor location were observed. Conclusions: Twelve
percent of KRAS negative colorectal cancer samples showed BRAF gene mutation.
Considering that 42% of samples have a KRAS mutation, 54% of patients should
not respond to therapies with monoclonal antibodies directed against epidermic
growth factor (EGFR) pathway.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Revista Médica de Chile 2014, vol.142,p.55-60
Keywords
Proto-Oncogene Proteins p21 (ras), Proto-Oncogene Proteins B-raf, Mutation, Colonic neoplasms